Instanosis Inc. focuses on commercialization of an innovative and broadly-applicable point-of-care platform to detect ultra-low concentrations of disease biomarkers, with the lead application being an ultrasensitive and low-cost COVID antigen test.

The technology is based on proprietary technology developed out of the Founder’s laboratory at Penn. This platform has many applications in Infectious Diseases, Cardiology, Neurology and other disease areas, where rapid, convenient and ultra-sensitive biomarker detection is crucial for disease detection and treatment.

Startup Details

Founded by:

Looking for: Partnerships, Seed Investment, Management

Contact: Neal Lemon.

Reference Dockets # 18-859420-9363

Skip to content